HALOZYME THERAPEUTICS, INC. (HALO) Stock
4 members of Congress disclosed 11 trades in HALO since 2017: 4 purchases and 7 sales, most recently Gilbert Cisneros (partial sale, Sep 29, 2026). 7 of the hedge funds AlphaScala tracks reported HALO in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $157.05M. Company insiders reported 0 open-market buys and 39 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded HALOZYME THERAPEUTICS, INC. (HALO)?
Most recent: Gilbert Cisneros (partial sale, Sep 29, 2026); records start Nov 6, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-09 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-03-24 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-09-09 | partial sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-07-12 | sale | $15k – $50k |
| Josh Gottheimer D-NJ · House | 2022-12-06 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2022-08-05 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2021-08-20 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all HALO political trades →Which hedge funds own HALO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 2.01M | $157.05M | +7% |
| Renaissance Technologies Jim Simons (founder) | 480K | $37.54M | -34% |
| Bridgewater Associates Ray Dalio | 463K | $36.25M | -9% |
| Citadel Ken Griffin | 289K | $22.63M | +51% |
| Marshall Wace | 188K | $14.74M | +56% |
| Hussman Investment Trust John Hussman | 25K | $2.78M | -40% |
| Millennium Management Israel Englander | 20K | $1.55M | -96% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are HALOZYME THERAPEUTICS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 8, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 4.8K | $520K |
| Oct 8, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 3.1K | $337K |
| Oct 8, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 11.9K | $1.3M |
| Oct 8, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 200 | $22K |
| Oct 7, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 8.6K | $955K |
| Oct 7, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 10.3K | $1.2M |
| Oct 7, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 900 | $102K |
| Oct 7, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 200 | $23K |
| Oct 6, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 2.3K | $248K |
| Oct 6, 26 | Torley Helen | PRESIDENT AND CEO | SELL | 6.0K | $656K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →HALO price chart
Powered by TradingViewWhat does HALOZYME THERAPEUTICS, INC. do?
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like monoclonal antibodies, therapeutic molecules, small molecules, and fluids, improving dispersion and absorption. Key products include Hylenex recombinant for enhancing subcutaneous drug delivery in medical imaging and XYOSTED for testosterone replacement therapy via auto-injector. The ENHANZE drug delivery technology is licensed to partners for co-formulation in treatments targeting oncology, endocrinology, and other areas, with recent approvals for products like RYBREVANT FASPRO, DARZALEX Faspro, and collaborations such as with Takeda for vedolizumab. Halozyme Therapeutics Inc. also expanded its portfolio through the acquisition of Elektrofi, adding high-concentration biologic formulations via Hypercon technology. Operating primarily in the United States with international reach, the company supports biopharmaceutical partners in creating patient-friendly therapies that enhance convenience, tolerability, and adherence. Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a vital role in advancing drug delivery innovations across therapeutic segments.